GLP-1 coverage limits
- Access to GLP-1 obesity drugs is expanding, but insurance rules still block many people from treatment. - NPR reports 88% with insurance face restrictions, and KFF says 56% of users find the drugs difficult to afford. - The federal government also shifted policy, agreeing to fund coverage through next year after insurer pushback. ( )
Insurance coverage for GLP-1 weight-loss drugs is widening in 2026, but most patients still run into insurer rules before they can fill a prescription. (goodrx.com) GoodRx reported this month that more than 88% of commercially insured people who do have coverage for GLP-1 or GIP-GLP-1 weight-loss drugs still face extra requirements such as prior authorization. KFF said on April 22 that 56% of GLP-1 users describe the drugs as difficult to afford. (goodrx.com) (kff.org) Those requirements usually mean an insurer asks a doctor to prove the patient meets body-mass-index rules, has related conditions, or has tried other treatment first. Employers and insurers also use quantity limits and step therapy to control use of drugs that can list for more than $1,000 a month. (usnews.com) (phti.org) GLP-1 drugs mimic a gut hormone that reduces appetite and slows stomach emptying, which is why demand for Wegovy and Zepbound has spread beyond diabetes care into obesity treatment. Coverage has not kept pace because Medicare has long been barred from covering drugs used only for weight loss, and Medicaid coverage is optional for states. (cms.gov) (kff.org) (congress.gov) The federal government tried to change that in December 2025, when the Centers for Medicare & Medicaid Services launched the voluntary BALANCE model for Medicaid and Medicare Part D. CMS said the model would let participating states and drug plans cover select GLP-1 drugs for weight management while pairing them with lifestyle support. (cms.gov 1) (cms.gov 2) For Medicare, CMS also created a temporary GLP-1 Bridge program scheduled to start July 1, 2026, while BALANCE was supposed to begin in Part D in 2027. KFF said CMS announced on April 21, 2026, that the Part D piece will not start in 2027 as planned and that the bridge program will instead run through 2027. (kff.org) (cms.gov) That change followed insurer resistance to the Medicare design. Bloomberg Law reported UnitedHealth Group and CVS Health had raised doubts about participating, and CMS delayed the Part D rollout after that pushback. (news.bloomberglaw.com) (aha.org) Medicaid is on a different track. KFF said the BALANCE model can begin in Medicaid in 2026, but participation is voluntary for states and drugmakers, and only 13 state Medicaid programs currently cover GLP-1 drugs for obesity treatment outside the model. (kff.org 1) (kff.org 2) Patients are also testing insurer limits in court. Bloomberg Law reported in December that class actions are challenging plan exclusions for GLP-1 weight-loss drugs, arguing that employers and insurers cannot draw such narrow coverage lines as obesity treatment becomes more common. (news.bloomberglaw.com) For now, access depends less on whether a drug works than on which card is in a patient’s wallet: an employer plan with prior authorization, a state Medicaid program that opts in, or a Medicare bridge that now has another year to run. (goodrx.com) (kff.org)
